Mitumprotimut T

Drug Profile

Mitumprotimut T

Alternative Names: B cell lymphoma vaccine - Favrille; FavId; Id-KLH vaccine; Non-Hodgkin's lymphoma vaccine - Favrille; Specifid

Latest Information Update: 31 Jul 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Favrille
  • Class Cancer vaccines
  • Mechanism of Action B cell modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Nov 2011 Mitumprotimut T is available for licensing as of 30 Nov 2011. www.mmrvideos.com
  • 15 Jun 2010 MMR Information Systems is now called MMRGlobal
  • 31 Jan 2009 MMR Information Systems acquires Favrille
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top